echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Significant improvement in dry eye symptoms New mechanism of action eye drops Phase 2 clinical results are positive

    Significant improvement in dry eye symptoms New mechanism of action eye drops Phase 2 clinical results are positive

    • Last Update: 2022-02-23
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Recently, Aldeyra Therapeutics announced positive top-line data from a Phase 2 clinical trial of its investigational therapy reproxalap eye drops in patients with dry eye disease
    .
    Both endpoints of the trial showed that patients who received reproxalap reported significantly lower scores for both ocular discomfort (p=0.
    002) and itching symptoms (p=0.
    01) compared to the active drug control group

    .

    In patients with dry eye, proinflammatory reactive aldehyde species (RASP) may contribute to ocular inflammation and changes in tear lipid composition
    .
    Reproxalap is a novel small molecule RASP inhibitor, which can reduce the level of RASP and achieve the effect of inhibiting inflammation and relieving symptoms

    .
    The therapy has been evaluated in more than 1,500 patients

    .
    It is currently being evaluated in a pivotal Phase 3 clinical trial, with results expected by the middle of this year

    .

    The double-blind, crossover, single-center Phase 2 clinical trial enrolled 56 patients with dry eye disease and evaluated the improvement in symptoms of 0.
    25% reproxalap compared to the approved prescription drug

    .
    No safety signals were observed in the trial, and no treatment-related discontinuations or drug-related moderate or serious adverse events occurred

    .
    The most common adverse event in both treatment groups was mild instillation site discomfort

    .

    Image source: Reference [1]

    Dry eye is one of the most common chronic eye diseases, affecting the quality of life of millions of people, causing persistent stinging, burning, sensitivity to light, blurred vision and eye strain
    .
    Damage to the tear film is one of the main causes of dry eye

    .
    The human tear film contains more than 1,500 different proteins, including growth factors and antibodies, as well as numerous classes of lipids and mucins that protect and lubricate the eye

    .
    At present, the main treatment method for dry eye is the use of artificial tears, but most patients fail to obtain satisfactory treatment results

    .

    References:

    [1] Aldeyra Therapeutics Announces Positive Top-Line Data from Phase 2 Dry Eye Chamber Clinical Trial of Reproxalap, an Investigational New Drug, Compared to Xiidra®.
    Retrieved January 11, 2022, from https://ir.
    aldeyra.
    com/news -releases/news-release-details/aldeyra-therapeutics-announces-positive-top-line-data-phase-2

    (Original abridged)

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.